Together Mental Health Clinic is Now REMS Certified to Provide SPRAVATO® (esketamine) CIII Nasal Spray Medication for Adults with Treatment-Resistant Depression.

Get to know Spravato ®  

  • Studied in adults with treatment-resistant depression
  • Nasal spray you self-administer under the supervision of a healthcare provide
  • Taken with an oral antidepressant
  • Greater reduction of depression symptoms at four weeks‡ (compared to those who received a placebo and oral antidepressant)
  • After 16 weeks of therapy, those patients who stayed on SPRAVATO®† did better than those who stopped therapy
  • Tell your healthcare provider if you have a history of drug or alcohol abuse
  • After you take SPRAVATO®, a healthcare provider will monitor you for at least two hours during the observation period for possible side effects. More About Side Effects

Spravato®  Safety  and Tolerability

  • SPRAVATO® nasal spray was evaluated for safety in both short- and long-term clinical trials of adults diagnosed with treatment-resistant depression
  • Do not take SPRAVATO® if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or are allergic to esketamine, ketamine or any of the ingredients in SPRAVATO®. Talk to your healthcare provider to learn more.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.